Direkt zum Inhalt
Merck
  • Surveillance of diversion and nonmedical use of extended-release prescription amphetamine and oral methylphenidate in the United States.

Surveillance of diversion and nonmedical use of extended-release prescription amphetamine and oral methylphenidate in the United States.

Journal of addictive diseases (2013-03-14)
Mark A Sembower, Michelle D Ertischek, Chloe Buchholtz, Nabarun Dasgupta, Sidney H Schnoll
ZUSAMMENFASSUNG

This article examines rates of nonmedical use and diversion of extended-release amphetamine and extended-release oral methylphenidate in the United States. Prescription dispensing data were sourced from retail pharmacies. Nonmedical use data were collected from the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System Drug Diversion Program and Poison Center Program. Drug diversion trends nearly overlapped for extended-release amphetamine and extended-release oral methylphenidate. Calls to poison centers were generally similar; however, calls regarding extended-release amphetamine trended slightly lower than those for extended-release oral methylphenidate. Data suggest similar diversion and poison center call rates for extended-release amphetamine and extended-release oral methylphenidate.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Supelco
(±)-Amphetamin -Lösung, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®